Immaculate Nankya

Immaculate Nankya

Auto-generated profile, based on publicly available information

Immaculate Nankya

Joint Clinical Research Centre

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2007
Verified
Journal Article
Closed access
DTDenis M Tebit
Denis M Tebit
INImmaculate Nankya
Immaculate Nankya
EAEric Arts
Eric Arts
YGYong Gao
Yong Gao

31 January 2020 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
AAAlisen Ayitewala
Alisen Ayitewala
FKFred Kyeyune
Fred Kyeyune
PAPamela Ainembabazi
Pamela Ainembabazi
ENEva Nabulime
Eva Nabulime
CKCharles Drago Kato
Charles Drago Kato
INImmaculate Nankya
Immaculate Nankya
Background: Resistance to antiretroviral drugs is a major challenge among Human Immunodeficiency Virus (HIV) positive patients receiving antiretroviral therapy (ART). Mutations that arise as a result of this are diverse across the various drugs, drug classes, drug regimens and subtypes. In Uganda, there is a paucity of information on how these mutations differ among the different drug regimens and the predominant HIV-1 subtypes. The purpose of this study was to determine mutation profile differences between first-line drug regimens: TDF/3TC/EFV and AZT/3TC/EFV and HIV-1 subtypes: A and D in Uganda. The study also investigated the potential usage of rilpivirine, doravirine and etravirine in patients who failed treatment on efavirenz.Methods: A retrospective study was conducted on 182 archived plasma samples obtained from patients who were experiencing virological failure between 2006 and 2017 at five Joint Clinical Research Center (JCRC) sites in Uganda. Sanger sequencing of the Reverse Transcriptase (RT) gene from codons 1–300 was done. Mutation scores were generated using the Stanford University HIV Drug Resistance Database. A Chi-square test was used to determine the association between drug resistance mutations (DRMs) and drug regimens or HIV-1 subtypes.Results: The prevalence of DRMs was 84.6% among patients failing a first-line efavirenz (EFV)-based regimen. The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%). While K103N (50.8%) and G190A/S/E/G (29.1%) were the most prevalent Non-Nucleoside Reverse Transcriptase Inhibitor (NNTRI) mutations. As expected, discriminatory DRMs such as K65R, L74I, and Y115F were noted in Tenofovir (TDF) containing regimens while the Thymidine Analogue Mutations (TAMs) L210W and T215 mutations were in Zidovudine (AZT)-based regimens. No significant difference (p = 0.336) was found for overall DRMs between HIV-1 subtypes A and D. Among the patients who had resistance to EFV, 37 (23.6%) were susceptible to newer NNRTIs such as Rilpivirine and Etravirine.Conclusion: Accumulation of DRMs between AZT/3TC/EFV and TDF/3TC/EFV is comparable but individual mutations that confer resistance to particular drugs should be considered at virological failure. Having either HIV-1 subtype A or D is not associated with the acquisition of DRMs, therefore HIV diversity should not determine the choice of treatment. Rilpivirine, etravirine and doravirine had minimal benefits for patients who failed on efavirenz.

22 January 2019 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
TTThe Ugandan Drug Resistance Study Team
The Ugandan Drug Resistance Study Team
APArt F. Y. Poon
Art F. Y. Poon
Emmanuel NdashimyeEmmanuel Ndashimye
Emmanuel Ndashimye
Mariano AvinoMariano Avino
Mariano Avino
RGRichard Gibson
Richard Gibson
EAEric Arts
Eric Arts
Our understanding of HIV-1 and antiretroviral treatment (ART) is strongly biased towards subtype B, the predominant subtype in North America and western Europe. Efforts to characterize the response to first-line treatments in other HIV-1 subtypes have been hindered by the availability of large study cohorts in resource-limited settings. To maximize our statistical power, we combined HIV-1 sequence and clinical data from every available study population associated with the Joint Clinical Research Centre (JCRC) in Uganda. These records were combined with contemporaneous ART-naive records from Uganda in the Stanford HIVdb database. Treatment failures were defined by the presence of HIV genotype records with sample collection dates after the ART start dates in the JCRC database. Drug resistances were predicted by the Stanford HIVdb algorithm, and HIV subtype classification and recombination detection was performed with SCUEAL. We used Bayesian network analysis to evaluate associations between drug exposures and subtypes, and binomial regression for associations with recombination. This is the largest database of first-line treatment failures ( $$n=1724$$ n = 1724 ) in Uganda to date, with a predicted statistical power of 80% to detect subtype associations at an odds ratio of $$\ge 1.2$$ ≥ 1.2 . In the subset where drug regimen data were available, we observed that use of 3TC was associated with a higher rate of first line treatment failure, whereas regimens containing AZT and TDF were associated with reduced rates of failure. In the complete database, we found limited evidence of associations between HIV-1 subtypes and treatment failure, with the exception of a significantly lower frequency of failures among A/D recombinants that comprised about 7% of the population. First-line treatment failure was significantly associated with reduced numbers of recombination breakpoints across subtypes. Expanding access to first-line ART should confer the anticipated public health benefits in Uganda, despite known differences in the pathogenesis of HIV-1 subtypes. Furthermore, the impact of ART may actually be enhanced by frequent inter-subtype recombination in this region.

11 March 2025 in AIDS Research and Therapy
Verified
Journal Article
Open access
INImmaculate Nankya
Immaculate Nankya
ENEva Natukunda
Eva Natukunda
DRDiana Rutebarika
Diana Rutebarika
CMChristine Matama
Christine Matama
RBRoy Basiimwa
Roy Basiimwa
CKCissy Kityo
Cissy Kityo
With the current elimination of mother to child transmission (EMTCT) of HIV, the number of HIV-positive newborns has greatly reduced. Some countries have successfully eliminated HIV infections among newborn babies. This study was nested within the DRIBS (Drug Resistance testing among Infants at Baseline Study), which enrolled 100 infants at the time of treatment initiation between 2017 and 2023. Infants were followed for two years. Viral load (VL) was measured every six months and after completion of the three sessions of intensified adherence counseling (IAC). IAC and HIV drug resistance testing were performed for VL greater than 1000 copies/ml. The median age at diagnosis was 79 (IQR, 57.75;140.75) days, with 4% of patients diagnosed within 6 weeks after delivery. The median age at the initiation of therapy was 110.5 (IQR, 87.0-162.0) days. The median baseline %CD4 was 26 (IQR, 18.75;32), with 9% of the babies being severely immunosuppressed (%CD4 < 15%). The median baseline log viral load was 4.44 (IQR, 3.19-5.58). At six months, 30% and 60% of the patients had a VL < 50 and < 1000 copies/ml, respectively. At 12 months, 36% and 69% of patients had a VL < 50 and < 1000 copies/ml, respectively. At 24 months, 63% and 83% had VL < 50 and < 1000 copies/ml, respectively. Post-IAC VL revealed that 35% of the children had low-level viremia (LLV) compared to mothers 11.5%. Kaplan-Meyer survival estimates showed that while it took 72 weeks for 50% of the mothers and infants to attain a VL less than 1000 copies/ml, it took 96 weeks for the infants to attain a VL < 50 copies/ml. A Viral load < 1000 copies/ml is achieved much more slowly in pediatric patients, implying that it might take longer for babies to achieve the third 95 (95% virally suppressed) of the UNAIDS targets. Furthermore, the greater prevalence of LLV in pediatric patients than in mothers has important implications for the response to therapy.

14 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
Mariano AvinoMariano Avino
Mariano Avino
Emmanuel NdashimyeEmmanuel Ndashimye
Emmanuel Ndashimye
Daniel J. LizotteDaniel J. Lizotte
Daniel J. Lizotte
AOAbayomi S. Olabode
Abayomi S. Olabode
RGRichard Gibson
Richard Gibson
APArt F. Y. Poon
Art F. Y. Poon
The global HIV-1 pandemic comprises many genetically divergent subtypes. Most of our understanding of drug resistance in HIV-1 derives from subtype B, which predominates in North America and western Europe. However, about 90% of the pandemic represents non-subtype B infections. Here, we use deep sequencing to analyze HIV-1 from infected individuals in Uganda who were either treatment-naïve or who experienced virologic failure on ART without the expected patterns of drug resistance. Our objective was to detect potentially novel associations between mutations in HIV-1 integrase and treatment outcomes in Uganda, where most infections are subtypes A or D. We retrieved a total of 380 archived plasma samples from patients at the Joint Clinical Research Centre (Kampala), of which 328 were integrase inhibitor-naïve and 52 were raltegravir (RAL)-based treatment failures. Next, we developed a bioinformatic pipeline for alignment and variant calling of the deep sequence data obtained from these samples from a MiSeq platform (Illumina). To detect associations between within-patient polymorphisms and treatment outcomes, we used a support vector machine (SVM) for feature selection with multiple imputation to account for partial reads and low quality base calls. Candidate point mutations of interest were experimentally introduced into the HIV-1 subtype B NL4-3 backbone to determine susceptibility to RAL in U87.CD4.CXCR4 cells. Finally, we carried out replication capacity experiments with wild-type and mutant viruses in TZM-bl cells in the presence and absence of RAL. Our analyses not only identified the known major mutation N155H and accessory mutations G163R and V151I, but also novel mutations I203M and I208L as most highly associated with RAL failure. The I203M and I208L mutations resulted in significantly decreased susceptibility to RAL (44.0-fold and 54.9-fold, respectively) compared to wild-type virus (EC 50 =0.32 nM), and may represent novel pathways of HIV-1 resistance to modern treatments. Author summary: There are many different types of HIV-1 around the world. Most of the research on how HIV-1 can become resistant to drug treatment has focused on the type (B) that is the most common in high-income countries. However, about 90% of infections around the world are caused by a type other than B. We used next-generation sequencing to analyze samples of HIV-1 from patients in Uganda (mostly infected by types A and D) for whom drug treatment failed to work, and whose infections did not fit the classic pattern of adaptation based on B. Next, we used machine learning to detect mutations in these virus populations that could explain the treatment outcomes. Finally, we experimentally added two candidate mutations identified by our analysis to a laboratory strain of HIV-1 and confirmed that they conferred drug resistance to the virus. Our study reveals new pathways that other types of HIV-1 may use to evolve resistance to drugs that make up the current recommended treatment for newly diagnosed individuals.

7 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
DKDaniel Karara
Daniel Karara
BBBernard S. Bagaya
Bernard S. Bagaya
FKFred Kyeyune
Fred Kyeyune
ENEva Nabulime
Eva Nabulime
PAPamela Ainembabazi
Pamela Ainembabazi
INImmaculate Nankya
Immaculate Nankya
IntroductionBy Sept 2018, only 59.3% of all HIV positive children on cART under 5 years were achieving virological suppression compared to 88.4% in the general population in Uganda. CCR5 promoter genotype specifically single nucleotide polymorphisms have been linked to modulate patient virological status. However, the few studies that have studied the association in infants have utilized allele-specific PCR a genotypic method limited to detecting already known SNPs. By using Sanger sequencing, we explored the association taking into account novel mutations. Methods Following ethical approvals, a cross sectional study was conducted using archived buffy coat samples from a pediatric HIV drug resistance study between May 2019 and January 2022 at the Joint Clinical Research Centre in Kampala, Uganda. 100 HIV seropositive infant buffy coat samples were sequenced for CCR5 SNP genotype following nucleic acid extraction, polymerase chain reaction and sanger sequencing. Odds ratios were used to determine the association between CCR5 SNPs and infant HIV plasma loads. Results 10 SNPs were identified with frequencies as follows; 58227G/A (21.8%), 58636A/G (28.7%), 58934T/G (74.7%), 59029G/A (48.3%), 59353T/C (55.2%), 59356C/T (23.0%), 59402G/A (94.2%) 59653C/T (66.7%), 59802A/C (34.5%), and 60024A/G (34.5%). Notably, 58227G/A, 58636A/G, 59802A/C, and 60024A/G are novel SNPs. However, none of these SNPs was significantly associated with infant virological failure but SNPs 59029G/A and 59353T/C showed higher odds of occurring in non-suppressors whereas 59356C/T and 59402G/A appeared to correlate with reduced plasma HIV loads. Infant virological suppression remained at 59% and in agreement with the national data. Conclusion Our study augments previous studies that CCR5 promoter SNPs play a role in modulating patient virological status however, strong conclusions could be drawn from either utilizing in-vitro studies or large epidemiological studies.